Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.46

0.11 (0.37%)

, BMY

Bristol-Myers

$50.05

0.71 (1.44%)

08:15
10/19/16
10/19
08:15
10/19/16
08:15

Roche Tecentriq approval increases competition, says Leerink

Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.

RHHBY

Roche

$29.46

0.11 (0.37%)

BMY

Bristol-Myers

$50.05

0.71 (1.44%)

MRK

Merck

$62.09

0.57 (0.93%)

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

  • 11

    Nov

RHHBY Roche
$29.46

0.11 (0.37%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
BMY Bristol-Myers
$50.05

0.71 (1.44%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/13/16
GSCO
10/13/16
DOWNGRADE
GSCO
Buy
Bristol-Myers downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Jami Rubin removed Bristol-Myers from the Conviction Buy List and lowered its price target to $67 from $75 saying disappointing CM-26 data adds a greater level of uncertainty to future trials. He continues to believe is well positioned for 2017, and view the shares as very attractive over the long-term.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$62.09

0.57 (0.93%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
BOFA
10/13/16
UPGRADE
Target $70
BOFA
Buy
Merck upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.

TODAY'S FREE FLY STORIES

BA

Boeing

$179.43

1.99 (1.12%)

17:39
02/27/17
02/27
17:39
02/27/17
17:39
Hot Stocks
Boeing awarded $678.7M government contract »

The Boeing Co., St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRGI

Fiesta Restaurant

$25.95

-0.4 (-1.52%)

17:37
02/27/17
02/27
17:37
02/27/17
17:37
Hot Stocks
Fiesta Restaurant suspends sale evaluation process »

For the past four months,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

IPWR

Ideal Power

$2.40

-0.03 (-1.23%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Ideal Power reports Q4 EPS (29c), consensus (29c) »

Reports Q4 revenue $400K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

KRA

Kraton Performance

$27.49

0.68 (2.54%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Kraton Performance reports Q4 EPS 29c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

FLGT

Fulgent Genetics

$11.46

0.23 (2.05%)

17:19
02/27/17
02/27
17:19
02/27/17
17:19
Earnings
Fulgent Genetics reports Q4 EPS 6c, consensus 4c »

Reports Q4 revenue $5.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

, FMER

FirstMerit

17:18
02/27/17
02/27
17:18
02/27/17
17:18
Hot Stocks
Old National names Michael Woods principal accounting officer »

Old National Bancorp…

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

FMER

FirstMerit

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$21.06

0.21 (1.01%)

17:17
02/27/17
02/27
17:17
02/27/17
17:17
Syndicate
Breaking Syndicate news story on Wabash »

Wabash files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTH

Anthera

$0.71

0.0142 (2.05%)

17:15
02/27/17
02/27
17:15
02/27/17
17:15
Earnings
Anthera reports Q4 EPS (36c), consensus (41c) »

The company ended the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$122.40

-0.33 (-0.27%)

17:13
02/27/17
02/27
17:13
02/27/17
17:13
Hot Stocks
Johnson & Johnson: DOJ inquires on Olysio, Massachusetts probes non-profit aid »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

ITGR

Integer

$36.95

0.55 (1.51%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
Integer announces Gary Haire joins company as CFO »

Integer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SHLM

A. Schulman

$33.75

0.05 (0.15%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
A. Schulman to open distribution center at Stryker, Ohio plant »

A. Schulman, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

SWX

Southwest Gas

$85.54

0.24 (0.28%)

17:10
02/27/17
02/27
17:10
02/27/17
17:10
Earnings
Southwest Gas reports Q4 EPS $1.37, consensus $1.35 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$34.18

0.98 (2.95%)

17:09
02/27/17
02/27
17:09
02/27/17
17:09
Hot Stocks
Dermira to present data from DRM04, olumacostat glasaretil clinical programs »

Dermira announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:08
02/27/17
02/27
17:08
02/27/17
17:08
Earnings
Albemarle sees FY17 adjusted EPS $4.00-$4.25, consensus $4.07 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
Albemarle reports Q4 adjusted cont ops EPS 78c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

RAIL

FreightCar America

$14.60

-0.04 (-0.27%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
FreightCar America reports Q4 EPS 1c, consensus 14c »

Reports Q4 revenue $…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:05
02/27/17
02/27
17:05
02/27/17
17:05
Earnings
ZTO Express sees Q1 revenue $360M-$374.4M, consensus $380.54M »

Representing a 27.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:03
02/27/17
02/27
17:03
02/27/17
17:03
Earnings
ZTO Express reports Q4 EPS 15c, consensus 16c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WUBA

58.com

$32.49

0.52 (1.63%)

17:02
02/27/17
02/27
17:02
02/27/17
17:02
Earnings
Breaking Earnings news story on 58.com »

58.com sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GLAD

Gladstone Capital

$9.22

0.1 (1.10%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Hot Stocks
Gladstone Capital announces investment in unified communications business »

Gladstone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.49

0.52 (1.63%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Earnings
58.com reports Q4 adjusted EPS 0c, consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PRGO

Perrigo

$84.68

0.25 (0.30%)

16:57
02/27/17
02/27
16:57
02/27/17
16:57
Hot Stocks
Perrigo down 11% after results, FY17 guidance, CFO change »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 21

    Mar

STZ

Constellation Brands

$157.80

-1.05 (-0.66%)

16:56
02/27/17
02/27
16:56
02/27/17
16:56
Hot Stocks
Breaking Hot Stocks news story on Constellation Brands »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Earnings
Breaking Earnings news story on AppFolio »

AppFolio sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

RDN

Radian Group

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Syndicate
Breaking Syndicate news story on Radian Group »

Radian Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.